Kezar Life Sciences, Inc. (KZR) News

Kezar Life Sciences, Inc. (KZR): $0.69

0.02 (-3.27%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add KZR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#168 of 355

in industry

Filter KZR News Items

KZR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KZR News From Around the Web

Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth

In the labyrinth of the stock market, discovering hidden gems often promises exhilarating prospects.

Yiannis Zourmpanos on InvestorPlace | December 18, 2023

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif., November 21, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL.

Yahoo | November 21, 2023

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., November 13, 2023--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Yahoo | November 13, 2023

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., November 03, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exercise price of $0.77 per share, the closing price of Kezar’s common stock on November 1, 2023, the gra

Yahoo | November 3, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

12 Best Penny Stocks to Buy Under $1

In this article, we will take a look at the 12 best penny stocks to buy under $1. To see more such companies, go directly to 5 Best Penny Stocks to Buy Under $1. Investors are optimistic as we move into the third quarter earnings season. Hopes in the Wall Street are growing that we […]

Yahoo | October 23, 2023

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Yahoo | October 4, 2023

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., October 03, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment is expected to extend operating capital to fund PALIZADE, Kezar’s Phase 2b clinical trial in lupus nephritis.

Yahoo | October 3, 2023

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

SOUTH SAN FRANCISCO, Calif., September 20, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today announced that it entered into a collaboration and license agreement with Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, to develop and commercialize zetomipzomib, Kezar’s

Yahoo | September 20, 2023

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., August 31, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September:

Yahoo | August 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!